Formycon Future Growth

Future criteria checks 5/6

Formycon is forecast to grow earnings and revenue by 31.5% and 33.4% per annum respectively. EPS is expected to grow by 27.2% per annum. Return on equity is forecast to be 13.4% in 3 years.

Key information

31.5%

Earnings growth rate

27.2%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	33.4%
Future return on equity	13.4%
Analyst coverage	Good
Last updated	18 Nov 2024

Recent future growth updates

Recent updates

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Nov 05

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Sep 04

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Jul 13

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Jun 02

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

May 23

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Feb 01

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

Sep 25

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

May 19

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Jan 04

Earnings and Revenue Growth Forecasts

XTRA:FYB - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	179	93	65	104	7
12/31/2025	91	10	-22	34	8
12/31/2024	60	-11	-67	-19	8
6/30/2024	61	64	-59	-33	N/A
3/31/2024	69	70	-45	-21	N/A
12/31/2023	78	76	-31	-10	N/A
9/30/2023	73	17	-43	-13	N/A
6/30/2023	69	-42	-54	-17	N/A
3/31/2023	56	-3	-50	-18	N/A
12/31/2022	42	36	-46	-19	N/A
9/30/2022	38	57	-32	-17	N/A
6/30/2022	34	77	-19	-16	N/A
3/31/2022	35	32	-17	-15	N/A
12/31/2021	37	-13	-14	-13	N/A
9/30/2021	37	-15	N/A	N/A	N/A
6/30/2021	38	-15	-12	-11	N/A
3/31/2021	36	-11	-9	-8	N/A
12/31/2020	34	-7	-5	-4	N/A
9/30/2020	33	-4	N/A	N/A	N/A
6/30/2020	32	-3	12	13	N/A
3/31/2020	33	-3	5	6	N/A
12/31/2019	33	-2	-2	-1	N/A
9/30/2019	34	-2	N/A	N/A	N/A
6/30/2019	36	-1	-17	-16	N/A
3/31/2019	39	3	-2	-1	N/A
12/31/2018	43	7	12	13	N/A
9/30/2018	44	8	10	11	N/A
6/30/2018	45	9	7	8	N/A
3/31/2018	37	4	N/A	2	N/A
12/31/2017	29	-2	N/A	-4	N/A
9/30/2017	24	-4	N/A	-3	N/A
6/30/2017	19	-6	N/A	-2	N/A
3/31/2017	19	-5	N/A	-4	N/A
12/31/2016	20	-4	N/A	-5	N/A
9/30/2016	18	-3	N/A	-4	N/A
6/30/2016	16	-2	N/A	-2	N/A
3/31/2016	16	-1	N/A	-1	N/A
12/31/2015	17	1	N/A	1	N/A
9/30/2015	19	0	N/A	0	N/A
6/30/2015	22	0	N/A	0	N/A
3/31/2015	17	0	N/A	0	N/A
12/31/2014	13	1	N/A	0	N/A
12/31/2013	0	-8	N/A	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FYB's forecast earnings growth (31.5% per year) is above the savings rate (1%).

Earnings vs Market: FYB's earnings (31.5% per year) are forecast to grow faster than the German market (21.1% per year).

High Growth Earnings: FYB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: FYB's revenue (33.4% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: FYB's revenue (33.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: FYB's Return on Equity is forecast to be low in 3 years time (13.4%).

Formycon Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to €0.70 loss

Consensus EPS estimates upgraded to €0.96 loss

Price target decreased by 8.7% to €87.00

Price target decreased by 12% to €96.25

Price target decreased by 7.9% to €103

Consensus EPS estimates fall by 146%

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Consensus EPS estimates upgraded to €0.70 loss

Consensus EPS estimates upgraded to €0.96 loss

First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Now 21% undervalued

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Share price stability

A Look At The Fair Value Of Formycon AG (ETR:FYB)

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift Shares

Price target decreased by 8.7% to €87.00

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 7.9% to €103

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S

We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 146%

Price target decreased by 8.6% to €116

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Consensus forecasts updated

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Consensus revenue estimates increase by 13%

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Consensus revenue estimates fall by 17%

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Price target increased to €87.00

Price target increased to €75.00

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Price target decreased to €70.00

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Consensus forecasts updated

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Consensus forecasts updated

Full year 2020 earnings released

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities